GMP – Page 17 – Pharma.Tips

Deviation history questioned during dossier submission – preventing PQ suspension

Addressing Deviation History During Dossier Submission to Prevent PQ Suspension Pharmaceutical organizations often face challenges with deviations that arise during the manufacturing process or quality control, particularly when submitting dossiers…

CAPA effectiveness doubted during requalification – how to defend manufacturing readiness

Defending Manufacturing Readiness Amidst Concerns Over CAPA Effectiveness During Requalification In the continually evolving landscape of pharmaceutical manufacturing, ensuring compliance with Good Manufacturing Practices (GMP) and maintaining a robust Quality…

Blend segregation risk during scale-up – process capability enhancement

Managing Blend Segregation Risks During Scale-Up for Enhanced Process Capability In the pharmaceutical manufacturing environment, blend segregation during scale-up poses significant challenges. This issue can lead to inconsistent product quality,…

Stability data gaps during dossier submission – preventing PQ suspension

“`html Addressing Gaps in Stability Data During Dossier Submission to Prevent PQ Suspension In the pharmaceutical industry, the integrity of stability data is paramount during dossier submissions for WHO Prequalification…

Stability data gaps during dossier submission – documentation gaps reviewers flag

“`html Addressing Stability Data Gaps During Dossier Submission for Regulatory Review In the complex landscape of pharmaceutical regulatory submissions, one common contention that businesses must navigate is the prevalence of…

API change not reported during inspection preparation – PQ assessment risk and mitigation

Addressing Unreported API Changes During Inspection Preparation: A Comprehensive Playbook In the ever-evolving landscape of pharmaceutical manufacturing, effective communication regarding Active Pharmaceutical Ingredient (API) changes is crucial for maintaining compliance…

Manual cleaning variability during validation lifecycle – inspection-ready cleaning optimization

Addressing Manual Cleaning Variability Throughout the Validation Lifecycle In pharmaceutical manufacturing, ensuring consistent cleaning processes is critical for maintaining product quality and compliance with regulatory standards. Variability in manual cleaning…

PQ dossier deficiency during WHO PQ assessment – CAPA expectations for PQ approval

Addressing PQ Dossier Deficiencies during WHO PQ Assessments: A Comprehensive Playbook for Pharma Professionals In today’s rapidly evolving pharmaceutical landscape, ensuring compliance with regulatory frameworks like the World Health Organization…

API change not reported during WHO PQ assessment – PQ assessment risk and mitigation

Mitigating Risks of Unreported API Changes during WHO PQ Assessments In the pharmaceutical industry, the integrity of Active Pharmaceutical Ingredients (APIs) is paramount, especially during the WHO Prequalification (PQ) assessments.…

API change not reported during WHO PQ assessment – CAPA expectations for PQ approval

Addressing Unreported API Changes During WHO PQ Assessments: A Practical Playbook In the fast-paced pharmaceutical manufacturing environment, maintaining compliance with WHO prequalification (PQ) standards is crucial for regulatory success. However,…

Inefficient CIP cycle during validation lifecycle – validated efficiency improvement

Improving Validation Efficiency for Inefficient CIP Cycles in Pharmaceutical Manufacturing In today’s competitive pharmaceutical landscape, maintaining efficiency in cleaning procedures, particularly during the validation lifecycle, is paramount. An inefficient Clean-In-Place…

Manufacturing site not PQ-ready during dossier submission – PQ assessment risk and mitigation

Navigating PQ Readiness Challenges in Pharmaceutical Manufacturing Manufacturers often face risks when their production sites are not fully ready for PQ assessments during dossier submissions. This situation can significantly impact…